Table 5.
Comparison between genders in the schizophrenia group.
| Schizophrenics | Z/t | P | Corhen’s d | ||
|---|---|---|---|---|---|
| Female (n = 194) |
Male (n = 292) |
||||
| Age (y) | 39.8 ± 12.1 | 39.0 ± 12.9 | 0.532 | 0.595 | – |
| Course (y) | 13.2 ± 12.7 | 11.0 ± 10.6 | 1.743 | 0.081 | – |
| Age at onset (y) | 26.6 ± 8.2 | 28.0 ± 8.5 | 1.881 | 0.060 | – |
| Body Mass Index (kg/m2) | 23.2 ± 3.9 | 23.9 ± 4.0 | 1.752 | 0.080 | – |
| CPZ-equivalent dose (mg/day)a | 325.0 ± 143.9 | 332.0 ± 152.0 | 0.463 | 0.644 | – |
| Total PANSS | 85.2 ± 11.3 | 85.8 ± 11.6 | 0.590 | 0.555 | 0.055 |
| Positive symptoms | 20.5 ± 5.5 | 18.9 ± 7.3 | 2.603 | 0.010 | 0.241 |
| Negative symptoms | 16.7 ± 4.6 | 18.4 ± 5.4 | 3.775 | 0.000 | 0.350 |
| General psychopathology | 37.2 ± 5.1 | 37.9 ± 5.3 | 1.555 | 0.121 | 0.144 |
| TSH (mIU/L) | 2.45 ± 1.58 | 1.85 ± 1.37 | 5.113 | <0.001 | 0.488 |
| TT3 (nmol/L) | 1.49 ± 0.27 | 1.64 ± 0.30 | 11.394 | <0.001 | 0.503 |
| FT3 (pmol/L) | 4.21 ± 0.74 | 4.66 ± 0.78 | 13.474 | <0.001 | 0.587 |
| TT4 (nmol/L) | 104.8 ± 21.9 | 102.2 ± 20.8 | 1.503 | 0.133 | 0.132 |
| FT4 (pmol/L) | 18.0 ± 3.5 | 18.2 ± 3.4 | 0.584 | 0.559 | 0.083 |
| ACTH (ng/L) | 26.8 ± 17.0 | 39.4 ± 25.6 | 5.994 | <0.001 | 0.588 |
| COR (nmol/L) | 474.7 ± 235.1 | 500.6 ± 199.0 | 1.758 | 0.079 | 0.132 |
PANSS, Positive and Negative Syndrome Scale; TSH, thyroid-stimulating hormone; TT3, total triiodothyronine; FT3, free triiodothyronine; TT4, total thyroxine; FT4, free thyroxine; ACTH, adrenocorticotrophic hormone and COR, cortisol; CPZ, chlorpromazine; a, derived from the antipsychotic treatment in the recurrent schizophrenia subgroup (n = 394, male/female = 222/172).